Oral News and Research

RSS

ADA commends HHS for reaffirming safety, efficacy of optimal community water fluoridation

The American Dental Association (ADA) today commended the Federal agencies responsible for public health and safety for recalibrating the ratio of fluoride to water that they consider optimal based on scientific evaluation and the full appreciation of fluoride received from all sources.

7 Jan 2011

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset, Inc., announced today positive data from interim analyses of two of its clinical programs: the HCV genotype 2 or 3 (GT2/3) arm of the PSI-7977 Phase 2b trial and the 14 day PSI-938 monotherapy cohort of the dual nucleotide study.

7 Jan 2011

Plexxikon, Genentech enter PLX4032 co-promotion agreement

Plexxikon, Inc., announced today that it has signed an agreement with Genentech to co-promote PLX4032 (RG7204) in the United States. PLX4032, an oral, novel kinase inhibitor that targets the oncogenic BRAF mutation, is being tested in late-stage clinical trials for the treatment of metastatic melanoma.

7 Jan 2011

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Anavex Life Sciences Corp. announced today that ANAVEX 2-73 has been named 2010's "most promising trial drug" by the editorial staff at Alzheimer's Weekly. The publication selected the ANAVEX 2-73 trial from a field of over 100 trials that treat dementias such as Alzheimer's and following the review of more than 10,000 articles.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Altheus Therapeutics, announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis.

6 Jan 2011

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2 (SGLT1 and SGLT2).

6 Jan 2011

J&JPRD submits New Drug Application to FDA for rivaroxaban

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application to the U.S. Food and Drug Administration for rivaroxaban, an investigational, oral, once-daily anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

6 Jan 2011

Columbia research team identifies bacteria may play a key role in atherosclerosis

Dr. Emil Kozarov and a team of researchers at the Columbia University College of Dental Medicine have identified specific bacteria that may have a key role in vascular pathogenesis, specifically atherosclerosis, or what is commonly referred to as "hardening of the arteries" - the number one cause of death in the United States.

6 Jan 2011

Nicotine replacement therapies to quit smoking

Although smoking is an expensive habit, let's face it, nicotine replacement therapies (NRT) to help you quit smoking can seem like expensive purchases as well.

6 Jan 2011

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease.

6 Jan 2011

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Water Street Healthcare Partners announced today that it has acquired OraPharma, Inc. from Johnson & Johnson. Water Street, a strategic private equity firm focused exclusively on health care, plans to build OraPharma into a leading specialty pharmaceutical company focused on dental and oral health care.

6 Jan 2011

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

Pico-Tesla, The Magneceutical Company, announced that it has commenced a randomized, double-blind, placebo-controlled pilot study of 30 patients who have Alzheimer's disease symptoms.

6 Jan 2011

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

DARA BioSciences, provided additional details from the recently completed Phase I clinical study for DB959, its PPAR delta/gamma agonist, an oral drug in development for the treatment of Type 2 Diabetes.

6 Jan 2011

Teva acquires Théramex

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of Théramex, Merck KGaA's European-based women's health business.

5 Jan 2011

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

According to the American Academy of Pediatrics, sweetened drinks are the primary source of added sugar in the daily diet of children. Each 12-ounce serving of a carbonated, sweetened soft drink contains the equivalent of 10 teaspoons of sugar and 150 calories. A child who consumes one can of regular soda needs to walk 45 minutes just to burn it off.

5 Jan 2011

Star Scientific plans to submit new, moist-snuff product for FDA evaluation

Star Scientific Inc.'s plan to submit a new, moist-snuff product for evaluation by the Food and Drug Administration as a "modified risk" tobacco product shows the vital importance of the new law giving the FDA the authority to regulate tobacco products and any health claims used to market them.

5 Jan 2011

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

Atherosclerosis is the leading cause of death in the developed world. While a number of risk factors for atherosclerosis have been defined, scientists continue to study other possible risk factors for this disease. Recent epidemiological and experimental studies link infectious agents with the development of inflammatory atherosclerosis. A hallmark of chronic infection with the oral pathogen Porphyromonas gingivalis is the induction of a chronic inflammatory response.

5 Jan 2011

CIGNA announces introduction of Dental Network Savings Program

CIGNA today announced the introduction of the Dental Network Savings Program, designed to provide Dental PPO and Dental Indemnity clients and customers additional savings opportunities when receiving covered dental plan services from a participating program dentist.

5 Jan 2011

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) has lifted a clinical hold on its Phase II, double-blind, adaptive-design, randomized, placebo-controlled, dose-ranging study of Alferon® LDO [oral interferon alfa-n3 (human leukocyte derived)] for the prevention and treatment of influenza.

5 Jan 2011

Oral News and Research

ADA commends HHS for reaffirming safety, efficacy of optimal community water fluoridation

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Plexxikon, Genentech enter PLX4032 co-promotion agreement

ANAVEX 2-73 named 2010's 'most promising trial drug' by Alzheimer's Weekly

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Altheus Therapeutics announces completion of Zoenasa phase I trial for ulcerative colitis

Lexicon Pharmaceuticals announces clinical trial, mechanistic study results of LX4211

J&JPRD submits New Drug Application to FDA for rivaroxaban

Columbia research team identifies bacteria may play a key role in atherosclerosis

Nicotine replacement therapies to quit smoking

Avaxia Biologics generates compelling pre-clinical data in animal models of IBD

Water Street Healthcare announces acquisition of OraPharma from Johnson & Johnson

Pico-Tesla commences placebo-controlled Magneceutical Therapy study for Alzheimer's disease

DARA BioSciences provides additional details of DB959 Phase I study for Type 2 Diabetes

Teva acquires Théramex

Sugared-sweetened beverages eliminated from Nationwide Children's Hospital campus

Star Scientific plans to submit new, moist-snuff product for FDA evaluation

P. gingivalis infection accelerates inflammation and atherosclerosis in the innominate artery

CIGNA announces introduction of Dental Network Savings Program

FDA lifts clinical hold on Hemispherx's Alferon LDO Phase II study for influenza prevention

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News